Published in Hum Pathol on January 01, 2003
FDG-PET/CT and parathyroid carcinoma: Review of literature and illustrative case series. World J Clin Oncol (2011) 1.19
Synchronous parathyroid carcinoma, parathyroid adenoma, and papillary thyroid carcinoma in a patient with severe and long-standing hyperparathyroidism. Endocr Pract (2009) 1.15
Parathyroid carcinoma: etiology, diagnosis, and treatment. World J Surg (2009) 0.93
The surgical management of renal hyperparathyroidism. Eur Arch Otorhinolaryngol (2011) 0.91
Normocalcemic parathyroid carcinoma: an unusual clinical presentation. World J Surg Oncol (2006) 0.86
Parathyroid adenoma. Head Neck Pathol (2008) 0.80
Differential RNA expression profile by cDNA microarray in sporadic primary hyperparathyroidism (pHPT): primary parathyroid hyperplasia versus adenoma. World J Surg (2006) 0.79
Octreotide uptake in parathyroid adenoma. Mol Imaging Radionucl Ther (2012) 0.78
Ectopic atypical parathyroid lipoadenoma: a rare cause of severe primary hyperparathyroidism. J Bone Miner Metab (2012) 0.78
[Pathology of parathyroid glands: Practical aspects for routine pathological investigations]. Pathologe (2015) 0.76
Molecular diagnosis in head and neck: what a surgical pathologist must know. Head Neck Pathol (2008) 0.75
Resection of a large ectopic parathyroid adenoma: A case report. Int J Surg Case Rep (2016) 0.75
Severe Hyperparathyroidism Versus Parathyroid Carcinoma: A clinical dilemma. Sultan Qaboos Univ Med J (2010) 0.75
Typifying the Atypical Parathyroid Adenoma. Indian J Nucl Med (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature (2004) 8.76
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet (2009) 8.69
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68
Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science (2003) 7.86
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med (2007) 6.55
Clinicopathologic correlates of solitary fibrous tumors. Cancer (2002) 5.96
An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet (2003) 5.82
Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell (2007) 5.62
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res (2005) 5.44
NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell (2007) 5.20
Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol (2006) 5.10
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med (2004) 5.01
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature (2005) 4.97
Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol (2007) 4.95
miR-19 is a key oncogenic component of mir-17-92. Genes Dev (2009) 4.95
Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol (2005) 4.79
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell (2006) 4.68
A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood (2002) 4.59
Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature (2004) 4.41
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg (2003) 4.25
Quality of complication reporting in the surgical literature. Ann Surg (2002) 4.21
Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest (2008) 4.13
Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med (2008) 3.98
Solid-pseudopapillary tumor of the pancreas: a surgical enigma? Ann Surg Oncol (2002) 3.96
Pasireotide for postoperative pancreatic fistula. N Engl J Med (2014) 3.84
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol (2008) 3.82
Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature (2005) 3.75
High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci U S A (2004) 3.75
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res (2002) 3.72
Identification of a tumour suppressor network opposing nuclear Akt function. Nature (2006) 3.68
Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol (2002) 3.60
Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol (2003) 3.56
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res (2009) 3.56
A selective approach to the resection of cystic lesions of the pancreas: results from 539 consecutive patients. Ann Surg (2006) 3.34
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol (2009) 3.26
Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg (2006) 3.23
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med (2013) 3.21
Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science (2003) 3.18
Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst (2004) 3.17
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst (2003) 3.15
Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer (2008) 3.10
Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature (2010) 3.09
PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature (2006) 3.01
Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg (2010) 2.99
Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev (2009) 2.99
Electronic synoptic operative reporting: assessing the reliability and completeness of synoptic reports for pancreatic resection. J Am Coll Surg (2010) 2.98
A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell (2006) 2.95
"MIATA"-minimal information about T cell assays. Immunity (2009) 2.90
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med (2011) 2.86
Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg (2004) 2.86
A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J (2005) 2.71
American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid (2012) 2.71
p63 expression profiles in human normal and tumor tissues. Clin Cancer Res (2002) 2.68
Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest (2006) 2.68
PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet (2010) 2.66
Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov (2013) 2.65
Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg (2004) 2.62
DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev (2008) 2.60
Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat Genet (2013) 2.59
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol (2006) 2.58
High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg (2003) 2.56
Tissue-specific and reversible RNA interference in transgenic mice. Nat Genet (2007) 2.54
Surgical treatment and outcomes of patients with primary inferior vena cava leiomyosarcoma. J Am Coll Surg (2003) 2.54
Adult spermatic cord sarcomas: management and results. Ann Surg Oncol (2003) 2.52
Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg (2002) 2.47
Paragangliomas of the head and neck. Oral Oncol (2004) 2.47
Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res (2002) 2.41
Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol (2006) 2.40
Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol (2002) 2.39
Long-term survival is superior after resection for cancer in high-volume centers. Ann Surg (2005) 2.38
Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg (2007) 2.37
Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J Clin Oncol (2003) 2.36
Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations. Proc Natl Acad Sci U S A (2007) 2.36
Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res (2003) 2.34
The influence of hospital and surgeon volume on in-hospital mortality for colectomy, gastrectomy, and lung lobectomy in patients with cancer. Surgery (2002) 2.32
Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res (2003) 2.32
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Adult genitourinary sarcoma: the 25-year Memorial Sloan-Kettering experience. J Urol (2006) 2.30
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet (2013) 2.29
Operative drainage following pancreatic resection: analysis of 1122 patients resected over 5 years at a single institution. Ann Surg (2013) 2.29
The value of splenic preservation with distal pancreatectomy. Arch Surg (2002) 2.27
American Surgical Association Blue Ribbon Committee Report on Surgical Education: 2004. Ann Surg (2005) 2.25
Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS One (2007) 2.25
Laparoscopic versus open distal gastrectomy for gastric cancer: a meta-analysis of randomized controlled trials and high-quality nonrandomized studies. Ann Surg (2012) 2.23